New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
07:10 EDTGEVASynageva announces active IND for SBC-103
Synageva BioPharma announced that the investigational new drug, or IND, application to the FDA to evaluate SBC-103 as a treatment for mucopolysaccharidosis IIIB, also known as Sanfilippo B syndrome, is active. The company plans to start enrolling patients with MPS IIIB in a Phase 1/2 study investigating intravenous administration of SBC-103 shortly and to report preliminary data from this study in 2015. The company recently completed a study assessing the integrity of the blood-brain barrier and other disease abnormalities in patients with MPS IIIB and plans to report data during the first quarter of 2015. The company is also conducting natural history studies in MPS IIIB. These include a retrospective natural history study of deceased MPS IIIB patients that began in July 2013 and a prospective, longitudinal natural history study in living MPS IIIB patients that began in September 2014.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use